Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease

  • Stefan Schreiber
  • , Raymond K. Cross
  • , Remo Panaccione
  • , Geert D'Haens
  • , Peter Bossuyt
  • , Iris Dotan
  • , Jean Frederic Colombel
  • , Edouard Louis
  • , Marla C. Dubinsky
  • , Kristina Kligys
  • , Ezequiel Neimark
  • , Alexandra Song
  • , Javier Zambrano
  • , Jasmina Kalabic
  • , Erica Cheng
  • , Yafei Zhang
  • , Marc Ferrante

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science